Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.
M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.
Group revenue rises to EUR 237 million (EUR 82 million in Q3-2020)
Beauty: treatment numbers at high level; record revenue in German practice network in October 2021; no negative impact from rising incidence rate of the Corona pandemic
Group EBITDA amounts to EUR 13.3 million (previous year: EUR 8.8 million); EBIT amounts to EUR 9.1 million (previous year: EUR 5.8 million); EBIT margin in the German practice network in the target corridor of 15-20% despite large number of new openings
After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year and the future.
M1 Kliniken AG announces figures for the first quarter of 2021. According to these figures, the consolidated group revenue of the M1 Group in the first quarter of the financial year 2021 rose by approx. 250% year-on-year to just under EUR 81 million (previous year: EUR 23 million). Of this, HAEMATO AG (without M1 Aesthetics), which was not yet consolidated in the same period of the previous year, accounted for sales of a good EUR 59 million.
M1 Kliniken AG publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.
M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.
M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind.
M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind.
We use cookies on our website.Some of them are essential, while others help us to improve this website and your experience.
Technically necessary tools that enable essential services and basic functions, including identity verification, service continuity and site security. This option cannot be denied.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Speichert die aktuelle PHP-Session.
Third-party content, e.g. stock widgets, are blocked by default. If third-party cookies are accepted, access to this content no longer requires manual consent.
We use the TradingView to display stock charts. This provider uses additional cookies to analyze its services.
By using this website, you consent to the use of cookies. You can find detailed information on the use of cookies on this website in the data protection declaration.